Tomatoes Recalled in 14 States Over Salmonella Concerns, FDA Warns
The US Food and Drug Administration (FDA) has announced a recall of tomatoes sold in 14 states due to potential salmonella contamination.
The recall involves two different brands: Ray & Mascari Inc. and Williams Farms Repack LLC. No illnesses have been reported so far, but consumers are urged to avoid consuming the recalled products.
Ray & Mascari Inc., based in Indiana, recalled four-count packs of Vine Ripe tomatoes sold in plastic clamshells. These tomatoes were distributed at Gordon Food Service Stores in 11 states, including New York, Illinois, Pennsylvania, and Michigan.
According to Today , the tomatoes were sold under the label "Vine Ripe Tomatoes" and had the statement "Packed by Ray & Mascari Inc." The affected lot numbers are RM250424 15250B and RM250427 15250B.
Williams Farms Repack LLC, located in South Carolina, also recalled several tomato products. These tomatoes, sold between April 23-28, 2025, were distributed to wholesalers in South Carolina, North Carolina, and Georgia.
Affected products include multiple package sizes of tomatoes, with lot codes R4467, R4470, and others. The tomatoes were sold under Williams Farms Repack and H&C Farms labels. FDA Warns of Salmonella Contamination in Tomatoes, Urges Return
Salmonella is a bacteria that can cause serious illness, especially in young children, the elderly, and people with weakened immune systems. Infections can lead to fever, diarrhea, vomiting, and stomach cramps.
While the FDA has not reported any illnesses connected to the tomatoes, they urge consumers to discard or return the products for a refund.
The tomatoes were supplied by Hanshaw & Caping Farms of Immokalee, Florida, which notified both companies about the possible contamination, CBS News said.
The FDA stated that while no illnesses have been linked to the tomatoes yet, it is crucial for consumers to act quickly to prevent potential health risks.
The affected tomatoes from Ray & Mascari Inc. were sold in the following states: Illinois, Indiana, Kentucky, Michigan, Missouri, Mississippi, New York, Ohio, Pennsylvania, Tennessee, and Wisconsin.
Meanwhile, the Williams Farms tomatoes were sold in South Carolina, North Carolina, and Georgia. If you purchased any of the recalled tomatoes, the FDA advises you to throw them away or return them to the store where you bought them.
For more information or questions, consumers can contact Jason Breland at Williams Farms Repack LLC at 843-866-7707 or 843-599-5154. For Ray & Mascari Inc., the contact number is 317-637-0234.
Originally published on vcpost.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
DW
4 days ago
- DW
Fecal transplants: Study is a 'wake-up call' for the field – DW – 06/06/2025
They are hailed as a promising method to restore gut microbiomes, but a study suggests fecal transplants may bring unintended health risks. Fecal microbial transplants (FMTs) can be traced back to the 4th Century, but it is only since their approval by the US Food and Drug Administration in past decade that the procedure has entered wide practice. They have been hailed as a treatment for Clostridium difficile or a common bacterial infection that can cause inflammation and gastrointestinal issues. The FDA first approved FMTs as a treatment for in 2013 and approved the first drug for FMT treatment in 2022. Some think FMTs may also be an option for treating Crohn's disease— a chronic autoimmune condition — ulcerative colitis and irritable bowel disorder. But researchers warned in a study published June 6, 2025, that FMTs may introduce microbes that could hijack the host environment to suit their needs and thrive, potentially introducing new health risks. The study, which was performed in mice, human tissue samples and with a small volunteer group, found "mismatches" between the donor fecal matter and destination gut environment could have unintended consequences on the recipient's immune and metabolic function. "Even a single FMT will cause a change in the host-microbe relationships in these very different regions of the bowel that may be very difficult to reverse," said Eugene Chang, the study's senior author and a professor of medicine at the University of Chicago, US, in a press statement. How does a fecal transplant work? Every human has a unique mix of microbes in their gastrointestinal tract — the gut. This includes trillions of bacteria, fungi, viruses and other microorganisms that perform biological duties within the body. Collectively, this collection of microbes is called gut flora. For some people, this ecosystem of microbes is disrupted by infections, autoimmune issues and other problems. This disrupted state is called gut dysbiosis. FMT donors need to meet a range of requirements: For instance, they must be free of blood-related infections, such as hepatitis and HIV, and they cannot have gut issues themselves. Doctors usually perform a colonoscopy to extract the donor's stool and, after further preparation, insert the donor microbes via a long tube into the recipient's gut. How does a Fecal Microbiota Transplant work? To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Colonizing the colon In the study, microbes were taken from three separate regions of the small and large intensities and implanted into mice recipients. Each batch of newly introduced gut flora appeared to take over — or, as described by the researchers, "terraform" — the entire intestinal tract of each mouse, rather than simply occupying the same region they originated from in the donor's gut. The colonizing microbes also transformed genes and proteins in the tissues of the recipient mice to make a more accommodating environment — even at a microbial level, these introduced species appeared to thrive. An assessment in seven human volunteers over a month also found high levels of microbe colonization in the small intestine. Because this caused modifications to immune and metabolic functions, the researchers say greater care should be given to designing fecal transplants that use specific, targeted microbes for the intestines. The gut is not only for digestion To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video A 'wake-up call' for the FMT field The study's lead author, Orlando DeLeon, University of Chicago, said it was a "wake-up call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there." OMT — omni microbial transplantation — administers a batch of good gut flora as a pill or through endoscopy, targeting specific intestinal regions with "matched" microbes. DeLeon said it's a better way forward for fecal transplants. "The microbes that were supposed to be there are better suited for it," said DeLeon, "so they're more naturally going to fill it even in the presence of other microbes." DW approached the research group for further comment but did not receive a response in time for publication. Ed Kuijper, an expert at the Leiden University Medical Centre, Netherlands, who was not involved in the study, told DW via email that the research "clearly demonstrates that FMT […] affects the microbiota composition throughout the entire intestinal tract, in both humans and mice." But Kuijper said he had concerns with the conclusion that FMT leads to "microbiota mismatches" and "unintended consequences" in various regions of the intestinal tract. Just as the research team acknowledged the limitations of only investigating seven human subjects over a month, Kuijper said a more extensive assessment in patients would be important to conclusively assess the potential negative health outcomes of fecal transplants. "A more appropriate conclusion would be that FMT induces changes in both the small and large intestines in mice, with systemic effects that vary depending on the region affected. It remains unclear if these changes persist in humans." In Europe, an inter-organization group called EurFMT exchanges research and information, and maintains a continental registry for patient follow-up. Edited by: Zulfikar Abbany
Int'l Business Times
20-05-2025
- Int'l Business Times
US Limits Covid Boosters To Over-65s Or Those At High Risk
The United States will limit Covid-19 boosters to people over 65 or those at risk of serious illness, while requiring vaccine makers to run fresh clinical trials before offering shots to younger and healthier individuals, officials said Tuesday. Writing in the New England Journal of Medicine, the Food and Drug Administration's Vinayak Prasad and Commissioner Martin Makary framed the policy shift as "evidence-based" and would align the United States more closely with guidance in Europe. But it comes as Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, pushes to remake federal public health policy. Kennedy previously led a nonprofit that was critical of immunization programs, and during the pandemic petitioned the FDA to revoke Covid vaccine authorizations, citing rare side effects including heart inflammation. Prasad and Makary praised the initial Covid-19 vaccine rollout as "a major scientific, medical, and regulatory accomplishment," but argued that the benefits of repeated boosters for low-risk individuals are uncertain. They criticized the US approach of recommending boosters for all adults regardless of age or health status, calling it a "one-size-fits-all" model based on the mistaken belief that Americans couldn't handle more nuanced, risk-based advice. Rather than building public trust, they wrote, it had backfired -- fueling vaccine hesitancy that has spilled over into skepticism toward childhood shots, including those for measles. The FDA said it would rely on lab test results to approve boosters for people who are over 65, or over six months old with at least one underlying condition. But for healthy individuals between six months and 64 years, regulators will now require data from randomized trials. "We simply don't know whether a healthy 52-year-old woman with a normal BMI (body mass index) who has had Covid-19 three times and has received six previous doses of a Covid-19 vaccine will benefit from the seventh dose," they wrote. Some infectious disease experts welcomed the shift. Amesh Adalja of Johns Hopkins University said it matched with the approach taken by other countries in a population that already carries significant immunity. "For lower-risk individuals, the goal has always been less clear, as protection against infection is transient and they don't have a high risk of severe disease," he told AFP. But others voiced concern about the practical consequences. Paul Offit, a leading vaccine expert at the Children's Hospital of Philadelphia, said it could limit access for people who still want boosters. "Any use, say in a healthy 35-year-old, would be considered off-label, and you wonder whether an insurance company would pay for it," he told AFP. Under the revised framework, companies like Pfizer and Moderna will be encouraged to test updated boosters in adults aged 50 to 64. These studies should measure whether the vaccines reduce symptomatic infections, hospitalizations and deaths. Rather than comparing new shots to earlier formulations, Prasad and Makary suggested placebo-controlled trials -- with saline as the comparator -- to better evaluate both benefit and potential side effects. The proposal, first floated by Kennedy earlier this month, has proved divisive. Critics argue that using a placebo -- when authorized vaccines already exist -- could expose participants to unnecessary harm. "Imagine if there was a death or two in the placebo group," said Offit. "I don't see how you conscience that." Supporters of continued Covid-19 boosters often draw parallels to annual flu shots. But Makary and Prasad pushed back on that comparison, arguing the genetic changes in Covid variants haven't been significant enough to justify automatically updating the vaccine each year. The FDA officials also sought to reassure Americans concerned they might lose access to boosters under the new framework. The Centers for Disease Control and Prevention's (CDC) definition of risk factors is "vast, including obesity and even mental health conditions such as depression," they wrote, noting that between 100 million and 200 million Americans would likely still qualify.
Int'l Business Times
14-05-2025
- Int'l Business Times
Over 75,000 Cases of Eye Drops Recalled Nationwide Over Sterility Concerns
Serbia's Novak Djokovic uses eye drops during a break as he plays Russia's Daniil Medvedev in the US Open tennis tournament men's singles final match at the USTA Billie Jean King National Tennis Center in New York on September 10, 2023. A major recall has been issued for over 75,000 cases of eye drop solutions sold nationwide after a safety concern was raised about the sterility of the products. The recall affects several ophthalmic solutions and was voluntarily initiated by BRS Analytical Service, a pharmaceutical testing lab. The recall was reported by AvKare, a company that manufactures and distributes medical and pharmaceutical products. The recall follows an audit by the US Food and Drug Administration (FDA) that uncovered manufacturing violations related to Good Manufacturing Practices (cGMP), NBC News said. These practices ensure that pharmaceutical products are produced under safe conditions to protect consumer health. According to AvKare, these deviations in manufacturing could result in products of poor quality, and there is a potential risk to patients who use these products. The FDA report specifically cited concerns about the lack of assurance that the recalled products were sterile. Sterility is crucial for eye care products, as contamination can lead to serious eye infections or other health complications. The affected products are commonly used to relieve dry or irritated eyes. The recall includes a variety of eye lubricants and ophthalmic solutions shipped between May 26, 2023, and April 21, 2025. If you have any of the following products, stop using them immediately: NDC# 50268-043-15 Artificial Tears Ophthalmic Solution NDC# 50268-066-15 Carboxymethylcellulose Sodium Ophthalmic Gel 1% NDC# 50268-068-15 Carboxymethylcellulose Sodium Ophthalmic Solution NDC# 50268-126-15 Lubricant Eye Drops Solution NDC# 50268-678-15 Polyvinyl Alcohol Ophthalmic Solution A pharmaceutical distributor issued an urgent notice about a voluntary recall for five over-the-counter eye care products over concerns with sterility. — First Coast News (@FCN2go) May 14, 2025 How to Return Recalled Eye Drops and Get a Refund These products are commonly used to treat dry eyes, but they may not meet the required safety standards. If you have any of the recalled eye drops, AvKare recommends filling out a Recall Form and sending it via email. According to USA Today , after submitting the form, you will receive a Return Authorization Form from the company. This form should be used to return the affected products to the following address: R&S Northeast LLC 8407 Austin Tracy Rd Fountain Run, KY 42133 Consumers will receive a full credit for the returned products, including shipping costs. If you are experiencing dry, itchy, or irritated eyes, experts suggest several alternatives to help relieve symptoms. Dr. Yuna Rapaport, a board-certified ophthalmologist, recommends using a warm compress over your eyes for 30 seconds each day to treat aqueous dry eye, also known as blepharitis. Additionally, using a humidifier in your bedroom can help ease symptoms of evaporative dry eye. Originally published on © {{Year}} All rights reserved. Do not reproduce without permission.
